A detailed history of Abrdn PLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Abrdn PLC holds 136,424 shares of NBIX stock, worth $17.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
136,424
Previous 161,147 15.34%
Holding current value
$17.1 Million
Previous $22.2 Million 29.2%
% of portfolio
0.03%
Previous 0.04%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$114.58 - $153.15 $2.83 Million - $3.79 Million
-24,723 Reduced 15.34%
136,424 $15.7 Million
Q2 2024

Aug 09, 2024

BUY
$130.86 - $143.19 $10.2 Million - $11.2 Million
77,935 Added 93.66%
161,147 $22.2 Million
Q1 2024

May 08, 2024

SELL
$130.4 - $143.74 $54,898 - $60,514
-421 Reduced 0.5%
83,212 $11.5 Million
Q4 2023

Jan 31, 2024

BUY
$106.07 - $132.76 $8.53 Million - $10.7 Million
80,420 Added 2502.96%
83,633 $11 Million
Q3 2023

Nov 06, 2023

SELL
$94.02 - $117.1 $25,291 - $31,499
-269 Reduced 7.73%
3,213 $361,000
Q2 2023

Jun 20, 2024

BUY
$89.53 - $104.87 $134,653 - $157,724
1,504 Added 76.04%
3,482 $328,000
Q2 2023

Aug 04, 2023

BUY
$89.53 - $104.87 $134,653 - $157,724
1,504 Added 76.04%
3,482 $328,000
Q1 2023

Jun 20, 2024

SELL
$94.11 - $123.02 $7.64 Million - $9.99 Million
-81,234 Reduced 97.62%
1,978 $200,000
Q1 2023

Apr 28, 2023

BUY
$94.11 - $123.02 $186,149 - $243,333
1,978 New
1,978 $200,000
Q2 2021

Aug 10, 2021

SELL
$89.43 - $102.27 $305,761 - $349,661
-3,419 Closed
0 $0
Q1 2021

May 06, 2021

BUY
$87.57 - $119.4 $22,330 - $30,447
255 Added 8.06%
3,419 $333,000
Q4 2020

Feb 10, 2021

BUY
$86.91 - $108.33 $30,070 - $37,482
346 Added 12.28%
3,164 $303,000
Q3 2020

Oct 21, 2020

SELL
$96.16 - $135.15 $219,533 - $308,547
-2,283 Reduced 44.76%
2,818 $271,000
Q2 2020

Aug 10, 2020

SELL
$85.09 - $130.36 $6.51 Million - $9.97 Million
-76,461 Reduced 93.75%
5,101 $622,000
Q1 2020

May 13, 2020

SELL
$75.11 - $113.76 $52,201 - $79,063
-695 Reduced 0.84%
81,562 $7.06 Million
Q4 2019

Feb 18, 2020

BUY
$86.8 - $118.57 $136,189 - $186,036
1,569 Added 1.94%
82,257 $8.84 Million
Q3 2019

Nov 13, 2019

SELL
$83.82 - $101.5 $1.64 Million - $1.99 Million
-19,608 Reduced 19.55%
80,688 $7.27 Million
Q2 2019

Aug 13, 2019

SELL
$72.24 - $91.27 $340,900 - $430,703
-4,719 Reduced 4.49%
100,296 $8.47 Million
Q1 2019

May 14, 2019

SELL
$69.31 - $91.53 $385,710 - $509,364
-5,565 Reduced 5.03%
105,015 $9.25 Million
Q4 2018

Feb 12, 2019

SELL
$68.32 - $124.36 $1.78 Million - $3.25 Million
-26,127 Reduced 19.11%
110,580 $7.82 Million
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $13.5 Million - $17.2 Million
136,707 New
136,707 $16.8 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.